Journal of Labelled Compounds and Radiopharmaceuticals—Vol. XXXVI, No. 10

SYNTHESIS OF DEUTERATED MOSAPRIDE CITRATE

Shiro Kato* and Yoshimi Hirokawa

Exploratory Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Enoki 33-94, Suita, Osaka 564, Japan

SUMMARY

The deuterium labeled form of mosapride citrate, a potential gastroprokinetic agent, was prepared *via* reduction of ethyl 4-(4-fluorobenzyl)-2-morpholinecarboxylate (**4**) with lithium borodeuteride.

Keywords: [$^2H_2$]-mosapride; gastroprokinetic agent; 5-HT_4 agonist; benzamide

INTRODUCTION

4-Amino-5-chloro-2-ethoxy-*N*-{[4-(4-fluorobenzyl)-2-morpholinyl]methyl}benzamide citrate (**1**, mosapride citrate) [1—3] is a potential gastroprokinetic agent without dopamine D_2 receptor antagonistic activity. The gastroprokinetic action is accepted to be correlated with agonistic activity at a new serotonin receptor subtype (5-HT_4) [4]. Mosapride citrate acts as a partial agonist for 5-HT_4 receptor and facilitates cholinergic transmission [5]. Clinical evaluations of **1** are ongoing. Metabolic studies required the synthesis of the deuterium labeled



citrate

1

CCC 0362–4803/95/100927–06

Received 21 December 1994
Revised 28 April 1995

form of mosapride. In this paper, we describe the facile of [$^2H_2$]-mosapride citrate *via* reduction of ethyl 4-(4-fluorobenzyl)-2-morpholinecarboxylate (**4**) with lithium borodeuteride.

RESULTS AND DISCUSSION



Scheme 1

The synthetic route is shown in Scheme 1. This route comprises the reduction of ethyl 4-(4-fluorobenzyl)-2-morpholinecarboxylate (**4**) with lithium borodeuteride. Beecham group reported that the reaction of 2-(benzylamino)ethanol with 2-chloroacrylonitrile gave 4-benzyl-2-morpholinecarbonitrile [6]. This method was applied for the morpholine ring synthesis; the treatment of 2-[(4-fluorobenzyl)amino]ethanol (**2**) with 2-chloroacrylonitrile afforded the

corresponding 2-cyanomorpholine **3**, which was converted to the intermediate ethyl morpholine-2-carboxylate **4** in a moderate yield. The reduction of **4** with sodium borodeuteride and lithium chloride in C_2H_5OH furnished [2-$^2H_2$]-4-(4-fluorobenzyl)-2-hydroxymethylmorpholine (**5**) in an excellent yield. Compound **5** was transformed into the phthalimide **6** using the Mitsunobu reaction [7]. The resultant **6** was treated with hydrazine to give the amine **7** in a good yield. Finally, the reaction of **7** with 4-amino-5-chloro-2-ethoxybenzoic acid [1] in the presence of 1-ethyl-3-[(3-dimethylamino)propyl]carbodiimide hydrochloride as a coupling agent, followed by the treatment of citric acid, afforded the desired [$^2H_2$]-mosapride citrate.

EXPERIMENTAL SECTION

All melting points were determined on a Yanagimoto micromelting point apparatus and are uncorrected. Ir spectra were recorded on a Hitachi 260-10 spectrometer. Electron ionization (EI) and secondary ion (SI) mass spectra (abbreviated as EIMS and SIMS, respectively) were obtained on a JEOL JMS D-300 spectrometer or a Hitachi M-80B spectrometer. ^{1}H-NMR spectra were taken at 200 MHz with a Varian GEMINI-200 spectrometer. Chemical shifts are expressed as δ (ppm) values with tetramethylsilane as an internal standard, and coupling constants (J) are given in Hz. Organic extracts were dried over anhydrous $MgSO_4$ or anhydrous Na_2SO_4. The solvent was evaporated under reduced pressure. Merck silica gel 60 (70—230 mesh) was used for column chromatography.

Ethyl 4-(4-fluorobenzyl)-2-morpholinecarboxylate (4) A solution of 2-[(4-fluorobenzyl)amino]ethanol [8] (**2**, 17.0 g, 0.10 mol) and 2-chloroacrylonitrile (9.7 ml, 0.12 mol) in $(C_2H_5)_2O$ (100 ml) was stirred at room temperature for 5 days. The solvent was evaporated to leave an oily residue, which was dissolved in 1,2-dimethoxyethane (300 ml). To the cooled solution was added potassium *tert*-butoxide (11.3 g, 0.10 mol). The mixture was stirred at room temperature for 2 h and then heated to reflux for 1h. After cooled to room temperature, saturated aqueous $NaHCO_3$ (100 ml) was added. The solution was extracted with $(C_2H_5)_2O$ and the extract was washed with brine. The solvent was evaporated to give a pale yellow oil, which was chromatographed on silica gel with $CHCl_3/CH_3OH$ = 50/1 to afford 13.6 g (62%) of 4-(4-fluorobenzyl)-2-morpholinecarbonitrile (**3**) as a colorless oil. ^{1}H-NMR ($CDCl_3$) δ: 2.39 (1H, ddd, J = 3.0, 9.0, 12.0, 5-H_{ax}), 2.47—2.70 (2H, m), 2.76 (1H, ddd, J = 1.5, 4.0, 12.0, 3-H_{eq}), 3.49 (1H, d, J = 13.0, C$\underline{H}_2$C$_6$H$_4$F), 3.57 (1H, d, J = 13.0, C$\underline{H}_2$C$_6$H$_4$F), 3.77 (1H, td, J = 3.5, 11.8, 6-H_{eq}), 4.02 (1H, ddd, J = 3.0, 9.0, 11.8, 6-H_{ax}), 4.60 (1H, t, J = 3.5,

2-H), 6.95—7.10 (2H, m, arom H), 7.25—7.40 (2H, m, arom H). SIMS *m/z*: 221, 220 (M^+), 219. IR (neat) ν cm^{-1}: 2230 (CN).

A mixture of **3** (1.0 g, 4.5 mmol), concentrated H_2SO_4 (1.3 ml), and C_2H_5OH (8 ml) was heated to reflux for 20 h and then cooled to room temperature. The solvent was evaporated to leave a residue, which was dissolved in water. The aqueous solution was basified with 20% aqueous K_2CO_3 and extracted with $(C_2H_5)_2O$. The extract was washed with brine. The solvent was evaporated to afford an oily residue, which was chromatographed on silica gel with ethyl acetate to give 1.2 g (98%) of **4** as a colorless oil. ^{1}H-NMR ($CDCl_3$) δ: 1.27 (3H, t, *J* = 7.0, $OCH_2C\underline{H}_3$), 2.23—2.43 (2H, m), 2.57 (1H, m), 2.91 (1H, ddd, *J* = 1.3, 3.0, 10.0, 3-H_{eq}), 3.45 (1H, d, *J* = 13.2, $C\underline{H}_2C_6H_4F$), 3.54 (1H, d, *J* = 13.2, $C\underline{H}_2C_6H_4F$), 3.69 (1H, ddd, *J* = 3.0, 9.5, 12.0, 6-H_{ax}), 4.02 (1H, td, *J* = 3.5, 12.0, 6-H_{eq}), 4.20 (1H, m), 4.22 (2H, q, *J* = 7.0, $OC\underline{H}_2CH_3$), 6.95—7.08 (2H, m, arom H), 7.20—7.35 (2H, m, arom H). SIMS *m/z*: 268 (MH^+), 266. IR (neat) ν cm^{-1}: 1725 (COOEt).

[2-$^2H_2$]-4-(4-Fluorobenzyl)-2-hydroxymethylmorpholine (5) To a mixture of **4** (1.2 g, 4.5 mmol), lithium chloride (0.38 g, 9.0 mmol), sodium borodeuteride (0.38 g, 9.0 mmol), and anhydrous tetrahydrofuran (THF, 10 ml) was added dropwise anhydrous C_2H_5OH (10 ml) at room temperature. The mixture was stirred at the same temperature for 15 h and concentrated to dryness. The residue was dissolved in water and then extracted with $CHCl_3$, and the extract was washed with brine. The solvent was evaporated to give a pale yellow oil, which was chromatographed on silica gel with ethyl acetate to afford 1.0 g (98%) of **5** as a colorless oil. ^{1}H-NMR ($CDCl_3$) δ: 2.00 (1H, t-like, *J* = 10.0, 3-H_{ax}), 2.19 (1H, dt, *J* = 3.5, 11.3, 5-H_{ax}), 2.68—2.76 (2H, m), 3.43 (1H, d, *J* = 13.0, $C\underline{H}_2C_6H_4F$), 3.52 (1H, d, *J* = 13.0, $C\underline{H}_2C_6H_4F$), 3.65 (1H, dd, *J* = 2.0, 10.0, 2-H), 3.71 (1H, dt, *J* = 2.2, 11.3, 6-H_{ax}), 3.90 (1H, ddd, *J* = 1.5, 3.5, 11.3, 6-H_{eq}), 6.92—7.10 (2H, m, arom H), 7.21—7.36 (2H, m, arom H). EIMS *m/z*: 227 (M^+), 164, 109.

[2-$^2H_2$]-*N*-[[4-(4-Fluorobenzyl)-2-morpholinyl]methyl]phthalimide (6) Dimethyl azodicarboxylate (0.64 g, 4.4 mmol) in anhydrous THF (3 ml) was added portionwise to a solution of **5** (1.0 g, 4.4 mmol), triphenylphosphine (1.2 g, 4.4 mmol), and phthalimide (0.65 g, 4.4 mmol) in THF (20 ml) at 0°C. The mixture was stirred at room temperature for 15 h and concentrated to dryness. The residue was dissolved in $CHCl_3$ and washed successively with water and brine. The solvent was evaporated to leave a solid, which was recrystallized from CH_3OH to give 1.5 g (96%) of **6**, mp 151—152°C. ^{1}H-NMR ($CDCl_3$) δ: 2.05 (1H, t-like, *J* =

11.0, 3-H_{ax}), 2.21 (1H, t, J = 10.0, 5-H_{ax}), 2.57 (1H, d, J = 11.0, 5-H_{eq}), 2.78 (1H, d, J = 10.0, 3-H_{eq}), 3.3—3.7 (3H, m, C$\underline{H}_2C_6H_4F$, 2-H), 3.8—4.0 (2H, m), 6.95—7.1 (2H, m, arom H), 7.2—7.4 (2H, m, arom H), 7.67—7.8 (2H, m, arom H), 7.8—7.93 (2H, m, arom H). SIMS *m/z*: 357 (MH^+), 313, 208, 136, 109. IR (KBr) ν cm^{-1}: 1755, 1700 [$N(CO)_2$]. *Anal.* Calcd for $C_{20}H_{17}D_2FN_2O_3$: C, 67.40; H, 4.81; D, 1.13; F, 5.33; N, 7.86. Found: C, 67.41; H, 4.70; D, 1.07; F, 5.50; N, 7.83.

[2-$^2H_2$]-2-(Aminomethyl)-4-(4-fluorobenzyl)morpholine (7) The mixture of **6** (1.5 mmol), 100% hydrazine monohydrate (0.32 g, 6.4 mmol), and C_2H_5OH (15 ml) was heated to reflux for 4 h and cooled to room temperature. After the reaction mixture was diluted with $CHCl_3$, the insoluble materials were filtered off. The filtrate was washed successively with a small amount of water and brine. The solvent was evaporated to leave 0.92 g of **7** as a pale yellow oil. ^{1}H-NMR ($CDCl_3$) δ: 1.63 (2H, br. s, NH_2), 1.85 (1H, dd, J = 10.0, 11.3, 3-H_{ax}), 2.15 (1H, dd, J = 3.5, 11.3, 5-H_{ax}), 2.58—2.76 (2H, m), 3.45 (2H, s, C$\underline{H}_2C_6H_4F$), 3.49 (1H, dd, J = 2.0, 10.0, 2-H), 3.67 (1H, dt, J = 2.5, 11.3, 6-H_{ax}), 3.87 (1H, ddd, J = 1.5, 3.5, 11.3, 6-H_{eq}), 6.92—7.07 (2H, m, arom H), 7.20—7.36 (2H, m, arom H). SIMS *m/z*: 227 (MH^+), 194, 109.

[$^2H_2$]-Mosapride citrate The mixture of 4-amino-5-chloro-2-ethoxybenzoic acid [1] (0.86 g, 4.0 mmol), **7** (0.9 g, 4.0 mmol), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (0.84 g, 4.4 mmol), CH_2Cl_2 (30 ml) was stirred at room temperature for 4 h. The reaction mixture was washed successively with water, 10% aqueous NaOH, water, and brine. The solvent was evaporated to give a pale yellow oil, which was chromatographed on silica gel with $CHCl_3/CH_3OH$ = 12/1 to furnish 1.6 g (93%) of [$^2H_2$]-mosapride as a colorless oil. Mosapride was converted to the citrate in the usual manner. Mp 131.5—132.5°C (CH_3OH—C_2H_5OH). ^{1}H-NMR (DMSO-d_6) δ: 1.38 (3H, t, J = 7.0, $OCH_2C\underline{H}_3$), 1.96 (1H, t-like, J = 11.0, 3-H_{ax}), 2.15 (1H, dt, J = 2.0, 11.0, 5-H_{ax}), 2.64 (2H, d, J = 15.5, citric acid), 2.73 (2H, J = 15.5, citric acid), 3.15—3.65 (2H, m), 3.54 (2H, s, C$\underline{H}_2C_6H_4F$), 3.84 (1H, d, J = 11.5, 6-H), 4.05 (2H, q, J = 7.0, $OC\underline{H}_2CH_3$), 5.94 (2H, s, NH_2), 6.46 (1H, s, arom 3-H), 7.1—7.23 (2H, m, arom H), 7.28—7.4 (2H, m, arom H), 7.70 (1H, s, arom 6-H), 8.04 (1H, s, CONH). SIMS *m/z*: 424 (MH^+). IR (KBr) ν cm^{-1}: 3360, 1720, 1630, 1580, 1540. *Anal.* Calcd for $C_{21}H_{23}ClD_2FN_3O_3 \cdot C_6H_8O_7$: C, 52.64; H, 5.07; Cl, 5.75; D, 0.65; F, 3.08; N, 6.82. Found: C, 52.39; H, 4.99; Cl, 5.52; D, 0.84; F, 3.08; N, 6.75.

ACKNOWLEDGMENT

We are grateful to the staff of the Analytical Chemistry Division of Exploratory Research Laboratories, Dainippon Pharmaceutical Company, for elemental analyses and spectral measurements.

REFERENCES

1. Kato S., Morie T., Kon T., Yoshida N., Karasawa T., and Matsumoto J.— J. Med. Chem. 34: 616 (1991)
2. Yoshida N., Omoya H., Oka M., Furukawa K., Ito T., and Karasawa T. — Arch. Int. Pharmacodyn. Ther. 300: 51 (1989)
3. Yoshida N., Kato S., and Ito T. — Drugs Future 18: 513 (1993)
4. Dumis A., Sebben M., and Bockaert J. —Naunyn-Schmiedeberg's Arch. Pharmacol. 340: 403 (1989)
5. Yoshida N. and Ito T. — Neurogastroenterol. Mot. 6: 197 (1994)
6. Beecham Group PLC, Jpn. Kokai Tokkyo Koho JP 62 30,785 (87 30,785) [Chem. Abstr., 106: 213963*k* (1987)
7. Mitsunobu O. — Synthesis 1981: 1
8. Kato S., Morie T., Harada H., Yoshida N., and Matsumoto J.— Chem. Pharm. Bull. 42: 877 (1994)